Last updated on August 2016

Study to Evaluate Induction Chemotherapy Using Docetaxel Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Nasopharyngeal Carcinoma
  • Age: Between 18 - 70 Years
  • Gender: Male or Female
  • Other:
    Recurrent T3N0-N1M0 NPC (by AJCC/UICC 6th edition) and at least 1 year from the end
    of last primary course of radiotherapy
    Age > 18 to < 70 years
    Performance status: < 1 by ECOG System (Appendix I)
    Adequate bone marrow & renal function
    Patients having Bilirubin =< 1.5 x ULN, ASAT & ALST=< 1.5 x ULN, Serum creatinine=<
    25 x ULN and / or Creatinine clearance >= 60ml/min
    Patients having WBC >= 3x10e9/L, Neutrophils 1.8x10e9/L, Platelets >= 100
    x10e9/L,Hemoglobin >=10g/dL
    Signed written informed consent
    Patients must have at least one measurable lesion

You may not be eligible for this study if the following are true:

  • Use of investigational agent within the past 28 days
    Pre-treatment with an anti-EGFR drug
    Severe cardiac disease such as heart failure, coronary artery disease or myocardial
    infarction within the last 12 months
    History of severe pulmonary diseases
    Active infection or other systemic disease under poor control
    Uncontrolled chronic neuropathy
    Know grade 3 or 4 allergic reaction to any of the components of the treatment
    Estimated life expectancy is less than 3 months
    Pregnancy or breast feeding

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.